<DOC>
	<DOCNO>NCT00439296</DOCNO>
	<brief_summary>This phase I/II study investigational drug call ABT-751 , produce Abbott Laboratories , give combination chemotherapy drug use treat acute lymphoblastic leukemia ( ALL ) come back ( recur ) . The phase I portion study do find high dose ABT-751 give safely combination chemotherapy drug . A safe dose one result unacceptable side effect . After safe dose ABT-751 give chemotherapy find , study add additional patient find ABT-751 ( give maximal safe dose ) give additional chemotherapy effective therapy treatment child relapse ALL . It expect approximately 15-35 child young adult take part study .</brief_summary>
	<brief_title>ABT-751 With Chemotherapy Relapsed Pediatric ALL</brief_title>
	<detailed_description>All patient receive 2 course chemotherapy unless medical complication prevent administration drug . Treatment first 2 course therapy last 2 month . Treatment study consist combination 8 anti-cancer medication . The 8 anticancer medicine ABT-751 , dexamethasone , PEG-asparaginase , doxorubicin , cytarabine ( Ara-C ) , methotrexate ( MTX ) , cyclophosphamide , 6-thioguanine . All drug except ABT-751 well know anti-cancer drug use extensively treatment cancer . During Phase I portion study , enroll , give assign dose ABT-751 . The dose ABT-751 base dos give previous study do adult child . At dose level ABT-751 , 3 6 child receive ABT-751 combination chemotherapy . If side effect severe , next group child receive high dose . The dose continue increase find dose cause serious side effect . Your dose ABT-751 increase . If bad side effect , dose may decrease . The dose use Phase 2 part study determine outcome Phase I study . The high dose use Phase I tolerate without serious side effect one use Phase 2 .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>This abbreviated list ... Patients must less 21 year age participate study . Patients must relapse acute lymphoblastic leukemia ( ALL ) without evidence central nervous system ( CNS ) disease . Patients must adequate kidney , heart liver function . Must able swallow capsule . Patients pregnant breast feed . Patients allergy Asparaginase product sulfacontaining medication . Patients active uncontrolled infection . Patients numbness tingle hand foot constipation .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Recurrence</keyword>
	<keyword>ABT-751</keyword>
	<keyword>Therapeutic Advances Childhood Leukemia</keyword>
	<keyword>Investigational</keyword>
	<keyword>Childhood</keyword>
	<keyword>ALL</keyword>
	<keyword>Relapsed ALL</keyword>
	<keyword>Refractory ALL</keyword>
	<keyword>Relapsed pediatric ALL</keyword>
	<keyword>Refractory pediatric ALL</keyword>
	<keyword>TACL</keyword>
</DOC>